The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1329
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Telavancin (Vibativ) for Gram-Positive Skin Infections

Telavancin (Vibativ– Astellas and Theravance), a lipoglycopeptide derivative of vancomycin (Vancocin, and others), has received FDA approval for treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria in adults.

MECHANISM OF ACTION — Telavancin inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function.

ACTIVITYIn vitro, telavancin is bactericidal against Staphylococcus aureus (including methicillin-resistant strains [MRSA]), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae (including penicillin-resistant isolates), Streptococcus angiosus group, and Enterococcus faecalis (vancomycin-susceptible isolates only).

Medical Letter consultants believe telavancin will prove to have no useful activity against ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1329
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian